Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2014; 20(42): 15727-15735
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15727
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15727
GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells
Xiao-Min Xin, Mu-Xiao Zhong, Gong-Li Yang, Yao Peng, Ya-Li Zhang, Wei Zhu, Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Xiao-Min Xin, Department of Gastroenterology, Anyang People’s Hospital, Anyang 455000, Henan Province, China
Gong-Li Yang, Department of Gastroenterology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China
Author contributions: Xin XM, Zhong MX and Yang GL contributed equally to this work; Xin XM, Zhu W and Zhang YL designed the research; Xin XM, Zhong MX, Yang GL and Peng Y performed the research; Xin XM, Zhu W and Zhang YL analyzed the data; and Xin XM, Zhong MX and Yang GL wrote the paper.
Supported by Guangdong Provincial Science and Technology Projects, No. 2011B050400009; and Scientific Research Projects of Hubei Province Education Department, No. B2014055
Correspondence to: Wei Zhu, PhD, Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou North Avenue, Baiyun District, Guangzhou 510515, Guangdong Province, China. chnz_w@126.com
Telephone: +86-20-61641533 Fax: +86-20-87280770
Received: March 14, 2014
Revised: June 13, 2014
Accepted: July 11, 2014
Published online: November 14, 2014
Revised: June 13, 2014
Accepted: July 11, 2014
Published online: November 14, 2014
Core Tip
Core tip: Our study emphasizes for the first time the effect of GW4064, a synthetic farnesoid X receptor (FXR) agonist, on the expression of adipokines and their receptors, and indicates that the way FXR agonist may act in the progress of nonalcoholic fatty liver disease (NAFLD) is at least partially through regulating the expression of adipokines and their receptors. Therefore, our data provide a further theoretical basis for using an FXR agonist in the therapeutic approach of NAFLD.